guest ::
| Home > Publications database > Generation of CAR-T cells using lentiviral vectors. > print |
| 001 | 178838 | ||
| 005 | 20240229143557.0 | ||
| 024 | 7 | _ | |a 10.1016/bs.mcb.2021.07.001 |2 doi |
| 024 | 7 | _ | |a pmid:35152998 |2 pmid |
| 024 | 7 | _ | |a 0091-679x |2 ISSN |
| 024 | 7 | _ | |a 0091-679X |2 ISSN |
| 024 | 7 | _ | |a DOI: 10.1016/bs.mcb.2021.07.001 |2 doi |
| 024 | 7 | _ | |a DOI: 10.1016/bs.mcb.2021.07.001 |2 doi |
| 037 | _ | _ | |a DKFZ-2022-00301 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 570 |
| 100 | 1 | _ | |a Poorebrahim, Mansour |0 P:(DE-He78)081f0df0551762b7dbb2faabe23023b5 |b 0 |e First author |u dkfz |
| 245 | _ | _ | |a Generation of CAR-T cells using lentiviral vectors. |
| 260 | _ | _ | |a New York, NY [u.a.] |c 2022 |b Elsevier |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1646913196_14513 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #EA:D122#LA:D122# |
| 520 | _ | _ | |a Cancer immunotherapy is nowadays largely focused on the development of therapeutic antibodies and chimeric antigen receptors (CARs). Two CARs targeting CD19 have been approved recently for the treatment of some hematological malignancies. This demonstrates the capability of engineered CAR T cells in generating effective tumor responses. Furthermore, several hundred ongoing clinical trials are exploring the feasibility of CAR-based approaches to target tumor-associated antigens in solid tumors. However, there still remain significant challenges and limitations in the design and production of CAR-modified T cells that need to be addressed, such as more effective transduction methods, expression and exhaustion issues, reliable in vitro and in vivo characterization methods, etc. Here we describe current techniques for generating CAR T cells using lentiviral vectors as well as detailed protocols for their functional characterization. |
| 536 | _ | _ | |a 314 - Immunologie und Krebs (POF4-314) |0 G:(DE-HGF)POF4-314 |c POF4-314 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef Book Series, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de |
| 650 | _ | 7 | |a CAR-T |2 Other |
| 650 | _ | 7 | |a Cell avidity analysis |2 Other |
| 650 | _ | 7 | |a Chimeric antigen receptor (CAR) |2 Other |
| 650 | _ | 7 | |a Electroporation |2 Other |
| 650 | _ | 7 | |a Jurkat |2 Other |
| 650 | _ | 7 | |a Lentiviral vector |2 Other |
| 650 | _ | 7 | |a PBMC |2 Other |
| 650 | _ | 7 | |a Transposon system |2 Other |
| 700 | 1 | _ | |a Quiros-Fernandez, Isaac |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Fakhr, Elham |0 P:(DE-He78)148613c9c06b4ac0e307b6fa7787fc9d |b 2 |u dkfz |
| 700 | 1 | _ | |a Cid-Arregui, Angel |0 P:(DE-He78)a30064f6b2d9ab959d35315d7668c091 |b 3 |e Last author |u dkfz |
| 773 | _ | _ | |a 10.1016/bs.mcb.2021.07.001 |0 PERI:(DE-600)2257731-2 |p 39-69 |t Methods in cell biology |v 167 |y 2022 |x 0091-679x |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:178838 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)081f0df0551762b7dbb2faabe23023b5 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-He78)148613c9c06b4ac0e307b6fa7787fc9d |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)a30064f6b2d9ab959d35315d7668c091 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-314 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Immunologie und Krebs |x 0 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b METHOD CELL BIOL : 2019 |d 2021-05-04 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2021-05-04 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2021-05-04 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2021-05-04 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-05-04 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2021-05-04 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1120 |2 StatID |b BIOSIS Reviews Reports And Meetings |d 2021-05-04 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1040 |2 StatID |b Zoological Record |d 2021-05-04 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-05-04 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2021-05-04 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2021-05-04 |
| 920 | 2 | _ | |0 I:(DE-He78)D122-20160331 |k D122 |l D122 AG Gezielte Tumorvakzine |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)D122-20160331 |k D122 |l D122 AG Gezielte Tumorvakzine |x 0 |
| 920 | 0 | _ | |0 I:(DE-He78)D122-20160331 |k D122 |l D122 AG Gezielte Tumorvakzine |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)D122-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|